This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Raptor Announces CEO Succession Plan; Dr. Christopher Starr To Retire As CEO At Year-end 2014, Julie Anne Smith Named President And CEO-Designate

NOVATO, Calif., July 7, 2014 (GLOBE NEWSWIRE) -- Raptor Pharmaceuticals (Nasdaq:RPTP) today announced that Julie Anne Smith, Executive Vice President, Strategy and Chief Operating Officer at Raptor, has been named President and CEO-designate effective immediately. Smith will succeed Christopher Starr, Ph.D., as Chief Executive Officer and will join the Board effective January 1, 2015. As President and CEO-designate, Smith will oversee all company operations based out of Raptor's headquarters in Novato, California. Dr. Starr will continue working closely with Smith during this transition period, will remain on the Board of Directors and will consult on Raptor development projects following the succession.

Dr. Starr, Ph.D., chief executive officer and Raptor co-founder, said, "It's been exciting and personally fulfilling to have led Raptor these past nine years. Since the beginning, our vision at Raptor has been to use innovative science to develop highly effective therapeutics to treat patients with rare, debilitating diseases. With last year's U.S. and EU PROCYSBI approvals, its successful initial launch, promising data in both Huntington's and NASH and a strong balance sheet, I am confident in Raptor's long-term outlook. Thus it is a great time to focus my energy on the next generation of therapeutic compounds at Raptor and to pursue other interests."

Llew Keltner, M.D., Ph.D., chairman of the Raptor board of directors, said, "Julie is a proven leader and has been instrumental in the launch and commercialization of Raptor's first product, PROCYSBI. She has a wealth of experience in commercializing products for rare disease and has had the opportunity to work alongside Chris to share in the vision and future direction of the company. The Board of Raptor wholeheartedly supports her nomination and has confidence in her ability to lead Raptor to achieve its full potential."

Dr. Keltner added, "The Board would like to thank Chris for his extraordinary leadership – initially creating Raptor with great science and vision and building it into a commercial organization that is now changing medicine and improving patients' lives around the world. We look forward to Chris' continued involvement and guidance on company research and strategy."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs